Amylyx Q3 net loss widens to $45.5 million as Phase 3 LUCIDITY trial meets primary endpoint
Amylyx reported a third-quarter 2026 net loss of $45.5 million, or $0.38 per share, up from $34.4 million, or $0.37 per share, a year earlier, as research and development and selling, general and administrative costs rose. The company also reported positive topline Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia and said a New Drug Application remains on track for submission by year-end 2026, while cash rose to $768.1 million after an equity offering with net proceeds of about $544.6 million.
Key points
- Net loss for the quarter ended September 30, 2026 was $45.5 million, or $0.38 per share, versus $34.4 million, or $0.37 per share, in the same period of 2025.
- R&D expenses were $28.4 million versus $19.9 million, and SG&A expenses were $21.3 million versus $16.2 million.
- LUCIDITY showed a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo, with a p-value of 0.000003.
- Cash, cash equivalents and marketable securities were $768.1 million at September 30, 2026, up from $250.8 million at June 30, 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.